Drugs/Recall·openFDA/drug

Ascend Laboratories, LLC — Class II: Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx On

MediumPublished May 20, 2026· AI-analyzed May 25, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Ascend Laboratories, LLC has initiated a Class II recall for Metoprolol Succinate Extended-Release Tablets (25 mg) due to failed dissolution specifications.

Who it affects

This affects Ascend Laboratories, LLC, the manufacturer Alkem Laboratories Ltd., and quality control personnel responsible for testing extended-release oral solids.

Why it matters

A failure in dissolution specifications for an extended-release product suggests potential issues with the controlled-release mechanism or formulation stability. This could lead to sub-therapeutic dosing or unintended release profiles, necessitating a review of manufacturing consistency and release testing procedures for the affected batches.

Practical takeaway

QA teams should review dissolution testing protocols and stability data for extended-release formulations. Verification of batch records and retention samples for the identified NDC may be necessary to ensure compliance with USP specifications.

FDA source material

Class II. Reason: Failed Dissolution Specifications. Product: Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.. Firm: Ascend Laboratories, LLC (Bedminster NJ United States). Status: Ongoing.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.